New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab [0.03%]
治疗血栓性微血管病的新靶点和新手段——Caplacizumab与Ravulizumab
Clement Chung
Clement Chung
Objective: To review the efficacy and safety of caplacizumab and ravulizumab for thrombotic microangiopathy. Data sources: A literature...
Dat Ngo,Jason Chen
Dat Ngo
Objective: To summarize and review the clinical data of Food and Drug Administration (FDA)-approved biosimilars for use in treatment of cancer and the current challenges health care institutions face when implementing a n...
Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma [0.03%]
治疗复发和难治性大B细胞淋巴瘤的CAR-T疗法(axicabtagene ciloleucel)临床数据
Zachery Halford,Mary Kate Anderson,Lunawati L Bennett
Zachery Halford
Objective: To evaluate the literature for axicabtagene ciloleucel (axi-cel), a first-in-class chimeric antigen receptor (CAR) T-cell therapy, in the treatment of relapsed/refractory (r/r) large B-cell lymphoma (LBCL). ...
Effectiveness of Quetiapine as a Sedative Adjunct in Mechanically Ventilated Adults Without Delirium [0.03%]
喹硫平作为非谵妄机械通气成人镇静辅助药物的有效性研究
Kelsey L Ohman,Jennifer M Schultheis,Shawn J Kram et al.
Kelsey L Ohman et al.
Background: Quetiapine is an atypical antipsychotic that is commonly used in the Intensive Care Unit (ICU). The utility of quetiapine as a sedative adjunct has not yet been evaluated, but has been described previously in ...
Comparative Study
The Annals of pharmacotherapy. 2021 Feb;55(2):149-156. DOI:10.1177/1060028020944409 2021
PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines [0.03%]
氯化氢毒素A-xvfs治疗中重度皱眉纹
Mary B Gadarowski,Rima I Ghamrawi,Sarah L Taylor et al.
Mary B Gadarowski et al.
Objective: PrabotulinumtoxinA-xvfs (Jeuveau), a botulinum toxin type A, was approved by the Food and Drug Administration for the temporary improvement in the appearance of moderate-to-severe glabellar lines in February 20...
A Systematic Review on the Use of Sacubitril/Valsartan Initiated Prior to Discharge in Hospitalized Patients With Heart Failure [0.03%]
一项系统性回顾：探讨沙库必利/缬沙坦在心力衰竭住院患者出院前使用的疗效及安全性
Krisy-Ann Thornby,Nicole M Maksutovic
Krisy-Ann Thornby
Objective: Systematically review the evidence of sacubitril/valsartan initiated in the hospital setting prior to discharge in patients with acute decompensated heart failure (HF). ...
Intravenous Immune Globulin (IVIG) for Treatment of Autoimmune Heparin-Induced Thrombocytopenia: A Systematic Review [0.03%]
静脉注射免疫球蛋白治疗自身免疫性肝素诱导的血小板减少症的系统评价
John A Dougherty,Robyn Lupoli Yarsley
John A Dougherty
Objective: To evaluate intravenous immune globulin (IVIG) for autoimmune heparin-induced thrombocytopenia (aHIT), including platelet recovery, IVIG dose, dosing weight, IVIG product used, and complications reported. ...
Safety of Intravenous Push Lacosamide Compared With Intravenous Piggyback at a Tertiary Academic Medical Center [0.03%]
tertiary Academic Medical Center的静脉推注拉考沙胺与静脉混合用药的安全性比较
Kevin McLaughlin,Shannon Carabetta,Nicholas Hunt et al.
Kevin McLaughlin et al.
Background: There are limited data regarding the incidence of adverse events associated with administering lacosamide by intravenous push (IVP) compared with IV piggyback (IVPB). ...
Tolerability of Highly Protein Bound Targeted Oral Oncolytic Drugs in Patients With Hypoalbuminemia: A Retrospective Analysis [0.03%]
低白蛋白血症患者使用高蛋白结合的靶向口服溶瘤药物的耐受性：一项回顾性分析
Joshua L Murdock,Marissa R Duco,David J Reeves
Joshua L Murdock
Background: Hypoalbuminemia is commonly observed in cancer patients. Given the pharmacokinetic interactions between serum proteins and protein bound medications, administration of highly protein bound targeted oral oncoly...
Leah B Herity,DaleMarie M Vaughan,Lindsey Ritenour Rodriguez et al.
Leah B Herity et al.
Objective: To review the pharmacological characteristics, clinical evidence, and place in therapy of voxelotor for the treatment of sickle cell disease (SCD). ...